GlassScriptPhysician profile
Anshu Varma
NPI 1275645558
$1,135.86
in general payments reported to CMS, 2019-2025
20 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2022: $30.26 · 2023: $171 · 2024: $485 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $167.21 | 2023-2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.92 | 2024-2025 | Jardiance |
| United Therapeutics Corporation | $116.24 | 2019 | |
| Abiomed | $97.44 | 2024 | Impella |
| Abbott Laboratories | $68.46 | 2022-2023 | Freestyle Libre 3 |
| Dexcom, INC. | $64.58 | 2023-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $63.06 | 2019 | |
| Abbvie INC. | $55.12 | 2024-2025 | |
| Novo Nordisk INC | $54.45 | 2024-2025 | Ozempic, Rybelsus |
| Exact Sciences Corporation | $52.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Stryker Corporation | $48.70 | 2024 | Everest Spinal System, Cascadia Interbody System |
| Astrazeneca Pharmaceuticals LP | $35.06 | 2024 | Breztri |
| Pfizer INC. | $28.94 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $20.49 | 2025 | Zoryve |
| Nevro Corp. | $19.76 | 2023 | Senza |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $18.36 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $17.75 | 2023 | Verquvo |
| Lundbeck LLC | $15.30 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $15.08 | 2024 | Trelegy Ellipta |
| Amgen INC. | $14.87 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anshu Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.